You are using an outdated browser. Please upgrade your browser to improve your experience.
MOST1

The Memory Orientation Screening Test (MOST™) is an easy to administer, highly reliable, and validated measure of cognitive functioning for older patients

The Memory Orientation Screening Test (MOST™) is an easy to administer, highly reliable, and validated measure of cognitive functioning for older patients

MOST1

by Clionsky Neuro Systems, Inc.
MOST1
MOST1
MOST1

What is it about?

The Memory Orientation Screening Test (MOST™) is an easy to administer, highly reliable, and validated measure of cognitive functioning for older patients.

MOST1

App Details

Version
1.2
Rating
NA
Size
3Mb
Genre
Medical Health & Fitness
Last updated
January 11, 2017
Release date
April 26, 2014
More info

App Screenshots

MOST1 screenshot-0
MOST1 screenshot-1
MOST1 screenshot-2
MOST1 screenshot-3
MOST1 screenshot-4

App Store Description

The Memory Orientation Screening Test (MOST™) is an easy to administer, highly reliable, and validated measure of cognitive functioning for older patients.

The MOST has been designed to use in a problem-oriented medical visit, a Medicare Annual Wellness Visit, and in hospital and rehabilitation settings. It takes less than five minutes to administer and score by staff members.

The MOST combines four tasks of memory and executive function into a 29-point score that accurately separates patients into normal, mildly cognitively impaired, or demented categories. Validation studies of the MOST have appeared in peer-reviewed journals.

FEATURES

- Built-in scoring assistance
- Automated score calculation and comparison of the current score with previous MOSTs or an MMSE.
- Generate and email a complete PDF report showing the MOST components and total score with the actual clock drawing
- Diagnostic classification and a series of research-supported care options included with summary report.
- You can email the report and download it to paper or include it in an EHR.

About Clionsky Neuro Systems, Inc.

CNS-Neuro is an emerging neuroscience company created to develop, deliver and support technology-based diagnostics and treatment protocols using a model of integrated scientific research and clinical practice. Its principals are Mitchell Clionsky, Ph.D. ABPP-CN, a board certified clinical neuropsychologist, and Emily Clionsky, M.D., an internist and psychiatrist. They are located in Springfield, MA.

At CNS-Neuro, we focus on patients at high risk for cognitive loss. We strive to improve patient outcomes and quality of life and provide care in the most efficient and cost effective way.